When Using Artificial Intelligence In Pharma R&D, Start With Identifying Problem To Solve

VeriSIM uses generative AI for questions such as changing a drug molecule’s chemistry and machine learning to better predict potential biological implications. “When a child is learning a language, you're teaching a child starting from A-to-Z structures, and then suddenly they start speaking. Then they start learning different things, and then they get into problem solving. That's really what AI is getting really good at now,” says CEO Jo Varshney.

VeriSIM Life's BioSIM “virtual drug development engine” narrows the number of drug compounds that offer anticipated value for the treatment or cure of specific illness or disease. • Source: VeriSIM Life

Artificial intelligence can provide paths for pharmaceutical firms to cut costs and time for getting additional OTC as well as Rx drugs to market. Their first step, says the CEO of a pharmaceutical AI developer, is determining the questions they need to answer.

“I ask people, what is the problem that you want me to solve instead of what kind of AI do you want to use? It's a simple change in the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Digital Technologies

More from HBW Insight

Proponent For Age-Restricting Diet Supplement Sales Adds ‘Health Inequities’ To Argument

 

Result of firms marketing weight loss products to Black and Latino girls and to lower-income households is to “worsen health inequities by gender, race, ethnicity and income,” says Harvard researcher Bryn Austin, director of Strategic Training Initiative for the Prevention of Eating Disorders.

US FDA Expert Panel Paints Bleak Picture For Future Of Talc In Cosmetics

 

The US FDA’s 20 May expert panel on talc discussed science behind the potential carcinogenicity of the cosmetic, food and drug ingredient, the importance of ‘good science’ in evaluating the substance and the need to find alternatives in each industry.

Self-Care Must Be Central To NHS Reform, Says UK Industry And Pharmacy Alliance

 
• By 

Ahead of a soon to be released 10-Year Health Plan for the English NHS, an alliance including PAGB calls for self-care to be “clearly recognised and supported through concrete policies that reflect its vital role in achieving the plan’s goals.”